Abstract
Current treatments available for osteoporosis until recently were active by inhibiting osteoclast activity and, thus, reducing bone remodelling. Intact PTH (PTH 1-84) and its analog, teriparatida (human recombinant PTH 1-34), are a new class of anabolic treatment of osteoporosis. It has been described a positive effect on bone microarchitecture and a reduction of the risk of new fractures due to a bone-forming mechanism. PTH must be considered as an useful alternative in the treatment of severe osteoporosis, both in men and women, in patients with several osteoporosis-related fractures or with a very low bone mineral density (T-score below -3.5) an a high risk for fracture. Other potential uses are glucocorticoid-induced and other secondary osteoporosis. The use of PTH is not recommended for more than 18 months for teriparatida and 24 months for PTH 1-84. Copyright © 2007 Aran Ediciones, s.l.
Original language | English |
---|---|
Pages (from-to) | 87-97 |
Journal | Anales de Medicina Interna |
Volume | 24 |
Issue number | 2 |
Publication status | Published - 1 Feb 2007 |
Keywords
- Anabolic
- Bone mineral density
- Fracture
- Osteoporosis
- Postmenopausal
- PTH
- Risk
- Treatment
- Women